Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment. The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduced Fc clinical-stage antibody, in combination with any anti-PD-1 and anti-PVRIG antibodies. The patent is set to expire no earlier than August 2037.
The company highlights that recent developments suggest potential advantages of anti-TIGITs without active Fc binder, like COM902. Their data indicates blocking TIGIT alone may be insufficient for optimal anti-tumor activity in certain cases, particularly in tumors non-responsive to PD-1 inhibition.
Compugen (NASDAQ: CGEN) ha ricevuto un nuovo brevetto negli Stati Uniti (N. 12152084) che copre l'uso della combinazione tripla del suo anticorpo anti-TIGIT COM902 con anticorpi anti-PD-1 e anti-PVRIG per il trattamento del cancro. Il brevetto rafforza il portafoglio IP di Compugen e protegge l'uso di COM902, un anticorpo clinico di tipo Fc ridotto, in combinazione con qualsiasi anticorpo anti-PD-1 e anti-PVRIG. Il brevetto scadrà non prima di agosto 2037.
La società sottolinea che gli sviluppi recenti suggeriscono potenziali vantaggi degli anti-TIGIT senza legante Fc attivo, come COM902. I loro dati indicano che il blocco di TIGIT da solo potrebbe essere insufficiente per un'attività anti-tumorale ottimale in alcuni casi, in particolare nei tumori non responsivi all'inibizione di PD-1.
Compugen (NASDAQ: CGEN) ha recibido una nueva patente en EE. UU. (N.º 12152084) que cubre el uso de la combinación triple de su anticuerpo anti-TIGIT COM902 con anticuerpos anti-PD-1 y anti-PVRIG para el tratamiento del cáncer. La patente fortalece el portafolio de propiedad intelectual de Compugen y protege el uso de COM902, un anticuerpo en etapa clínica de tipo Fc reducido, en combinación con cualquier anticuerpo anti-PD-1 y anti-PVRIG. La patente expirará no antes de agosto de 2037.
La compañía destaca que los desarrollos recientes sugieren ventajas potenciales de los anti-TIGIT sin un ligante Fc activo, como COM902. Sus datos indican que bloquear TIGIT solo puede ser insuficiente para una actividad anti-tumoral óptima en ciertos casos, particularmente en tumores no respondientes a la inhibición de PD-1.
Compugen (NASDAQ: CGEN)은 암 치료를 위해 COM902 항-TIGIT 항체와 항-PD-1 및 항-PVRIG 항체의 삼중 조합 사용을 포함하는 새로운 미국 특허(번호 12152084)를 받았습니다. 이 특허는 Compugen의 지적 재산 포트폴리오를 강화하고, 모든 항-PD-1 및 항-PVRIG 항체와의 조합에서 임상 단계의 Fc 축소형 항체인 COM902의 사용을 보호합니다. 이 특허는 2037년 8월 이전에는 만료되지 않습니다.
회사는 최근 개발이 COM902와 같이 활성 Fc 결합제가 없는 anti-TIGIT의 잠재적 이점을 시사한다고 강조합니다. 그들의 데이터는 TIGIT 단독 차단이 특정 경우, 특히 PD-1 억제에 반응하지 않는 종양에서 최적의 항종양 활성에는 불충분할 수 있음을 나타냅니다.
Compugen (NASDAQ: CGEN) a obtenu un nouveau brevet américain (n° 12152084) couvrant l'utilisation en combinaison triple de son anticorps anti-TIGIT COM902 avec des anticorps anti-PD-1 et anti-PVRIG pour le traitement du cancer. Ce brevet renforce le portefeuille de propriété intellectuelle de Compugen et protège l'utilisation de COM902, un anticorps de stade clinique à Fc réduit, en combinaison avec tout anticorps anti-PD-1 et anti-PVRIG. Le brevet expirera au plus tôt en août 2037.
L'entreprise souligne que des développements récents suggèrent des avantages potentiels des anti-TIGIT sans liaison Fc active, comme COM902. Leurs données indiquent que le blocage de TIGIT seul peut être insuffisant pour une activité anti-tumorale optimale dans certains cas, en particulier dans les tumeurs non réactives à l'inhibition de PD-1.
Compugen (NASDAQ: CGEN) hat ein neues US-Patent (Nr. 12152084) erhalten, das die Anwendung der dreifachen Kombination seines COM902 Anti-TIGIT-Antikörpers mit Anti-PD-1- und Anti-PVRIG-Antikörpern zur Krebsbehandlung abdeckt. Das Patent stärkt das IP-Portfolio von Compugen und schützt die Verwendung von COM902, einem klinischen Antikörper mit reduzierter Fc, in Kombination mit allen Anti-PD-1- und Anti-PVRIG-Antikörpern. Das Patent läuft nicht vor August 2037 ab.
Das Unternehmen hebt hervor, dass aktuelle Entwicklungen potenzielle Vorteile von Anti-TIGITs ohne aktiven Fc-Binder wie COM902 nahelegen. Ihre Daten zeigen, dass die Blockade von TIGIT allein in bestimmten Fällen möglicherweise unzureichend für eine optimale anti-tumorale Aktivität ist, insbesondere bei Tumoren, die nicht auf PD-1-Hemmung ansprechen.
- New U.S. patent granted extending protection until August 2037
- Patent covers broad combination therapy applications with any anti-PD-1 and anti-PVRIG antibodies
- Strengthens intellectual property portfolio in cancer immunotherapy
- Data suggests COM902 alone may be insufficient for optimal anti-tumor activity
- Additional combination therapies may be required for effective treatment
Insights
This patent issuance significantly strengthens Compugen's competitive position in the immuno-oncology space. The broad method-of-use protection for COM902 in triple combination therapy extends until 2037, creating a substantial barrier to entry for competitors. The patent's scope is particularly valuable as it covers combinations with any anti-PD-1 and anti-PVRIG antibodies, not just Compugen's specific formulations. This flexibility in combination therapy options enhances potential partnership opportunities and licensing revenue streams. The reduced Fc binding characteristic of COM902 appears to be a differentiating feature in the increasingly competitive TIGIT inhibitor landscape, potentially offering improved efficacy compared to conventional TIGIT antibodies.
The strategic value of this patent lies in its alignment with emerging clinical evidence suggesting that multi-checkpoint inhibition may be necessary for optimal anti-tumor responses. The reduced Fc binding of COM902 represents a potentially significant therapeutic advantage, as recent data indicates this characteristic may be important for TIGIT inhibitor efficacy. The triple combination approach targeting TIGIT, PD-1 and PVRIG simultaneously addresses multiple immune checkpoint pathways, which could be particularly beneficial in treating PD-1 resistant tumors. The upcoming adaptive platform trial for COM701 will be important in validating this multi-targeted approach and establishing its potential as a backbone therapy.
- Broad method of use patent protection for COM902, a potential best-in-class reduced Fc, clinical stage, anti-TIGIT antibody, in triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer
- Further strengthens Compugen's IP portfolio across DNAM-1 axis checkpoint inhibitors
HOLON,
"Protecting COM902 in combination with any anti-PVRIG antibody and any anti-PD-1 antibody is an important part of our strategy to bring innovative treatments to patients and value to our shareholders," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. "Recent developments in the TIGIT landscape point to the potential advantage of anti-TIGITs without an active Fc binder such as COM902. Our data also suggest that blocking TIGIT may be insufficient to provide optimal anti-tumor activity in certain tumor types, including those non-responsive to PD-1 inhibition, and blocking PD-1 and PVRIG in parallel may be needed to provide optimal benefit. In our next study we plan to evaluate our potential first-in-class, anti-PVRIG antibody, COM701, in an adaptive platform trial designed to first establish its monotherapy benefit and as a potential backbone for future drug combinations, including with COM902, anti-PD-1 and others."
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class reduced Fc antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which has been granted IND clearance from the FDA, is licensed to Gilead. Compugen is headquartered in
Forward-Looking Statement
This press release contains "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations, and assumptions of Compugen. Forward-looking statements can be identified using terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statement regarding the potential advantage of anti-TIGITs without an active Fc binder, such as COM902; statements indicating that blocking TIGIT may be insufficient to provide optimal anti-tumor activity in certain tumor types, including those non-responsive to PD-1 inhibition; statements to the effect that blocking PD-1 and PVRIG in parallel may be needed to provide optimal benefit; and statements regarding our next study. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance, or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen may not be able to advance its internal clinical stage programs through clinical development or manufacturing or successfully partner or commercialize them, or obtain marketing approval, either alone or with a collaborator, or may experience significant delays in doing so; clinical development involves a lengthy and expensive process, with an uncertain outcome and Compugen may encounter substantial delays or even an inability to begin clinical trials for any specific product or may not be able to conduct or complete its trials on the timelines it expects; Compugen has limited experience in the development of therapeutic product candidates, and it may be unable to implement its business strategy; the general market, political and economic conditions in the countries in which Compugen operates, including
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:SOURCE Compugen Ltd.
FAQ
What is the new patent granted to Compugen (CGEN) for COM902?
When will Compugen's (CGEN) new COM902 patent expire?
What are the limitations of Compugen's (CGEN) COM902 treatment?
